Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26072852 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Christian Domingo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma…. Hauptthemen laut MEDLINE: Omalizumab, Immunoglobulin E, Asthma, Adrenal Cortex Hormones. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, FIS.
Abstract (Originalsprache)
To date, no biomarkers have been found that are able to predict the clinical response to omalizumab. The aim of this study was to assess whether blood concentration of free Immunoglobulin E (IgE) can predict response to treatment with this monoclonal antibody. In a group of patients who were candidates for omalizumab treatment, forced spirometry and blood IgE were measured at entry and at each six-month visit, and free-IgE blood concentrations were measured at month 6. At month 18, the OMADORE protocol was applied. The complete follow-up lasted 30 months. Patients were considered responders if they met at least one of the following criteria: increase in forced expiratory volume in one second (FEV1) at the follow-up visit compared to baseline; reduction in corticosteroid dose at the last visit compared to baseline; reduction in omalizumab dose at the follow-up visit; a positive score on the composite index combining all three criteria. The biomarker used to predict treatment response was the free IgE value and the percentage of free IgE to total IgE measured at visit 1, after six months of omalizumab treatment. The percentage of responders varied according to the parameter used (FEV1, omalizumab, corticosteroid dose, and the composite index; 45.2%, 64.5%, 48.4%, and 77.4%, respectively). IgE blockade was around 97% both for the group as a whole and for the subgroups. There were no differences in free IgE values nor in the ratio of free IgE to total IgE between responders and non-responders. These results confirm that there is a group of patients who may benefit from the reduction/withdrawal of omalizumab. Determination of free IgE six months after initiation of omalizumab treatment does not discriminate between responders and non-responders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, 08208 Sabadell, Barcelona, Spain.
- Clinical Research Division of Molecular and Clinical Allergotoxicology, Department of Dermatology and Allergy, Technische Universität München, 80802 Münich, Germany.
- Heorfy Consulting, 25007 Lleida, Spain.
- Department of Basic Medical Sciences, University of Lleida, 25198 Lleida, Spain.
- Pharmacy Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, 08208 Sabadell, Barcelona, Spain.
- Laboratory Department, Immunology Unit, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, 08208 Sabadell, Barcelona, Spain.
ORCID-Profile: Christian Domingo, Daniel-Ross Monserrate, Markus Ollert, Xavier Pomares, Carles Forné, Jorge Del Estal, María José Amengual
Förderung
- Ministry of Health
- FIS
Zitieren
APA
Domingo, C., Monserrate, D. R., Ollert, M., Pomares, X., Forné, C., Del Estal, J., & Amengual, M. J. (2025). Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26072852
Vancouver
Domingo C, Monserrate DR, Ollert M, Pomares X, Forné C, Del Estal J, et al. Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26072852
BibTeX
@article{Domingo2025,
author = {Domingo, Christian and Monserrate, Daniel-Ross and Ollert, Markus and Pomares, Xavier and Forné, Carles and Del Estal, Jorge and Amengual, María José},
title = {Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26072852}
}
EUVIMED